Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

348
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
348
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.9K
Overview
67.9K
Dialysis01:27

Dialysis

278
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies.

Frontiers in immunology·2026
Same author

Viewpoint on donor-derived cell-free DNA: context of use and clinical utility are key.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

The Role of Natural Killer Cells in Kidney Transplantation.

Transplantation·2026
Same author

Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation.

Science translational medicine·2026
Same author

Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Related Experiment Video

Updated: Jun 15, 2025

Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.6K

Chronic Rejection After Kidney Transplantation.

Matthias Diebold1,2, Katharina A Mayer1, Luis Hidalgo3

  • 1Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Transplantation
|August 28, 2024
PubMed
Summary

Natural killer (NK) cells are key drivers of chronic kidney transplant rejection. Felzartamab, targeting CD38 on NK cells, shows promise in treating antibody-mediated rejection and improving graft survival.

More Related Videos

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

15.7K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K

Related Experiment Videos

Last Updated: Jun 15, 2025

Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.6K
Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

15.7K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Alloimmune processes, often due to HLA incompatibilities, cause chronic rejection in kidney transplants.
  • Antibody-mediated rejection (AMR) involves microvascular inflammation where natural killer (NK) cells are critical effectors.
  • Current therapies for transplant rejection remain limited, highlighting an unmet clinical need.

Purpose of the Study:

  • To investigate the role of NK cells in chronic kidney transplant rejection.
  • To evaluate the efficacy of felzartamab, a CD38-targeting monoclonal antibody, in treating late antibody-mediated rejection.

Main Methods:

  • Analysis of immunohistologic evidence, bulk and spatial transcriptomics, and functional genetics.
  • Exploratory phase 2 clinical trial of felzartamab in patients with late AMR.

Main Results:

  • NK cells are identified as pivotal effector cells in the microvascular inflammation characteristic of AMR.
  • Felzartamab demonstrated potential in resolving molecular and morphologic rejection activity and injury in late AMR.
  • The therapeutic effect of felzartamab appears to be primarily mediated by targeting NK cell effector function.

Conclusions:

  • NK cells play a crucial role in the pathogenesis of chronic kidney transplant rejection.
  • Felzartamab shows promise as a novel therapeutic agent for antibody-mediated rejection by targeting NK cells.
  • Further pivotal trials are necessary to confirm the efficacy of felzartamab in chronic transplant rejection.